Rani Therapeutics Holdings, INC 8-K filings

Rani Therapeutics announced second quarter 2026 financial results, highlighting positive initial Phase 1a data for RT-114, a $20 million capital raise, and a new collaboration with PegBio.

Rani Therapeutics Holdings, Inc. announced the appointment of Michelle Gilson to its Board of Directors and as chair of the Audit Committee, effective August 1, 2026.

Rani Therapeutics Holdings, Inc. announced significant corporate governance changes, including the termination of its Tax Receivable Agreement and a reduction in Class B common stock voting power, effective December 31, 2025.

Rani Therapeutics announced a significant collaboration with Chugai Pharmaceutical, an oversubscribed private placement, and extended its cash runway into 2028, alongside reporting Q3 2025 financial results.

Rani Therapeutics Holdings, Inc. announced the appointment of two new directors and the closing of a private placement, significantly impacting its board composition and capital structure.

Rani Therapeutics Holdings, Inc. announced a $60.3 million private placement, a debt conversion, and a strategic collaboration with Chugai Pharmaceutical for an oral hemophilia product.

Rani Therapeutics announced its second quarter 2025 financial results, highlighted by a new research collaboration with Chugai and progress on its oral obesity treatment, RT-114, despite a significant decrease in cash reserves.

Rani Therapeutics Holdings, Inc. has entered into a securities purchase agreement with an institutional investor to raise approximately $3.0 million through the sale of Class A common stock and pre-funded warrants.

Rani Therapeutics Holdings, Inc. has received a notice from Nasdaq regarding non-compliance with the minimum bid price requirement, potentially leading to delisting if not rectified by December 17, 2025.

Rani Therapeutics Holdings, Inc. announced that all proposals, including the re-election of its seven director nominees and the ratification of CBIZ CPAs P.C. as its independent auditor, were approved by stockholders at its Annual Meeting held on May 28, 2025.

Rani Therapeutics Holdings, Inc. has entered into a letter agreement with an existing institutional investor, resulting in $4.3 million in gross proceeds through warrant exercises and the issuance of a new Series D warrant.

Rani Therapeutics reports promising preclinical data for its oral biologics delivery platform and announces its first quarter 2025 financial results, highlighting progress in obesity treatment development.

Rani Therapeutics received a notice from Nasdaq for failing to meet the minimum market value requirement, placing its listing at risk.

Laureen DeBuono retires from Rani Therapeutics' Board of Directors, leading to a reconstitution of board committees.

Rani Therapeutics Holdings, Inc. announces the resignation of Marcum LLP as its independent registered public accounting firm and the appointment of CBIZ CPAs P.C. as its new auditor, effective April 7, 2025.

Rani Therapeutics reports positive preclinical data on oral delivery of obesity treatments and announces financial results for Q4 and full year 2024.

Rani Therapeutics reported its third quarter 2024 financial results, highlighted by new preclinical data and the completion of two equity offerings totaling $20 million.

Rani Therapeutics has entered into a securities purchase agreement for a $10 million offering, including shares, pre-funded warrants, and common warrants.

Rani Therapeutics Holdings, Inc. has dismissed Ernst & Young LLP as its independent auditor and appointed Marcum LLP, effective September 10, 2024.

Rani Therapeutics has partnered with ProGen to develop an oral obesity treatment and reported its second quarter 2024 financial results, including a net loss of $13.4 million.

Rani Therapeutics Holdings, Inc. has entered into a securities purchase agreement for a private placement expected to generate approximately $10 million in gross proceeds.

Rani Therapeutics has decided not to proceed with a potential equity financing after evaluating its business development, cash position, and market conditions.

Rani Therapeutics and ProGen Co., Ltd. have entered a collaboration to develop and commercialize an oral weight management product combining ProGen's GLP-1/GLP-2 dual agonist with Rani's oral delivery device.

Rani Therapeutics held its annual meeting on May 29, 2024, where stockholders elected directors and ratified the appointment of Ernst & Young as the company's auditor.

Rani Therapeutics reported positive topline results from a Phase 1 study of its oral anti-interleukin 12/23 antibody (RT-111) and provided a corporate update along with its first quarter 2024 financial results.

Rani Therapeutics reported positive topline results from a Phase 1 study of its oral anti-interleukin 12/23 antibody and provided a corporate update, including extending its cash runway into 2025.

Rani Therapeutics reports successful Phase 1 trial results for its oral ustekinumab biosimilar, RT-111, showing high bioavailability and good tolerability.